- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Sotorasib Significantly Improves PFS Vs Docetaxel for KRAS G12C–Mutated NSCLC
September 12th 2022, 2:31pm
Sotorasib doubled the rate of progression-free survival at 12 months and reduced the risk of progression or death by 34% compared with docetaxel for patients with previously treated non–small cell lung cancer with KRAS G12C mutations.
Atezolizumab Shows Substantial OS Improvement in Platinum-Ineligible NSCLC
September 12th 2022, 2:30pm
Atezolizumab led to an almost doubling in the rate of 2-year overall survival compared with vinorelbine or gemcitabine in patients with advanced platinum-ineligible non–small cell lung cancer.
Neoadjuvant Cemiplimab Elicits Encouraging Pathologic Complete Response in CSCC
September 12th 2022, 2:21pm
Cemiplimab produced pathologic complete responses as a neoadjuvant treatment in more than half of patients with resectable, stage II to IV cutaneous squamous cell carcinoma.
Adjuvant Canakinumab Misses DFS Primary End Point in NSCLC
September 12th 2022, 2:00pm
Patients with completely resected non–small cell lung cancer did not derive a significant benefit with adjuvant canakinumab vs placebo.
Tislelizumab Provides Favorable Efficacy in Asian and Non-Asian Patients with Previously Treated Advanced NSCLC
September 12th 2022, 1:00pm
Tislelizumab continued to demonstrate an improved clinical benefit compared with docetaxel in both Asian and non-Asian patients with previously treated advanced non–small cell lung cancer.
Apalutamide Plus ADT Elicits PSA PFS Benefit in High-Risk, Biochemically Relapsed Prostate Cancer
September 11th 2022, 10:00pm
Intensification of androgen-deprivation therapy plus apalutamide displayed promising efficacy in patients with high-risk, biochemically relapsed prostate cancer.
Neoadjuvant Nivolumab/Ipilimumab Elicits Promising Pathologic Responses in dMMR Colon Cancer
September 11th 2022, 9:35pm
Four weeks of treatment with nivolumab plus ipilimumab elicited major pathologic responses in 95% of patients with mismatch repair–deficient colon cancer.
Addition of Neoadjuvant Pembrolizumab Improves EFS in Resectable Melanoma
September 11th 2022, 8:40pm
Compared with adjuvant pembrolizumab alone, the addition of neoadjuvant pembrolizumab significantly improved event-free survival outcomes for patients with stage III-IV melanoma with a hazard ratio of 0.58.
Dr. Patel on the Neoadjuvant Administration of Pembrolizumab in Advanced Melanoma
September 11th 2022, 8:02pm
Sapna Patel, BA, MD, discusses the neoadjuvant administration of pembrolizumab in advanced melanoma.
Dr. Petrylak on Enzalutamide Plus Androgen Deprivation Therapy in mHSPC
September 11th 2022, 8:02pm
Daniel P. Petrylak, MD, discusses enzalutamide plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer.
Updated ADAURA Data Reinforce Adjuvant Osimertinib as SOC for EGFR-Mutated, Stage IB-IIIA NSCLC
September 11th 2022, 7:20pm
Adjuvant osimertinib resulted in a 77% reduction in the risk of disease recurrence or death in patients with EGFR-mutated, stage II to IIIA non–small cell lung cancer, with a disease-free survival improvement observed irrespective of prior adjuvant chemotherapy or disease stage.
Destiny-Breast04 Update Showcases QOL Benefit With Trastuzumab Deruxtecan for HR+, HER2-Low Breast Cancer
September 11th 2022, 6:35pm
Trastuzumab deruxtecan demonstrated a promising quality-of-life benefit for patients with hormone receptor–positive, HER2-low metastatic breast cancer, according to a report on patient-reported outcomes from the pivotal DESTINY-Breast04 trial.
High-Dose MEDI5752 Induces Clinical Benefit in NSCLC at the Cost of Significant Toxicity
September 11th 2022, 6:18pm
MEDI5752 plus chemotherapy doubled the duration of response and extended survival compared with pembrolizumab in patients with treatment-naïve nonsquamous non–small cell lung cancer.
Olaparib/Abiraterone Continues to Provide Superior Clinical Benefit Over Abiraterone Alone in Frontline mCRPC
September 11th 2022, 5:50pm
The combination of olaparib plus abiraterone acetate and prednisone or prednisolone demonstrated a continuing trend toward an overall survival benefit when used in the first-line treatment of patients with metastatic castration-resistant prostate cancer.
DCC-3116 Displays Early Tolerability in RAS/RAF-Mutant Solid Tumors
September 11th 2022, 5:02pm
The ULK1/2 inhibitor DCC-3116 was well tolerated as a monotherapy in patients with locally advanced or metastatic tumors harboring a RAS or RAF mutation.
POU2F2 May Be Predictive of Survival Benefit With Maintenance Avelumab in Urothelial Carcinoma
September 11th 2022, 4:55pm
The absence of POU2F2, may be predictive of response to maintenance avelumab in patients with advanced or metastatic urothelial carcinoma, according to findings from an analysis peripheral blood samples taken in the JAVELIN Bladder 100 trial.
Rucaparib Maintenance Elicits PFS Benefit in Newly Diagnosed Ovarian Cancer
September 11th 2022, 4:30pm
ESMO Congress: Gynecologic Cancers
First-line rucaparib maintenance therapy improved progression-free survival vs placebo in patients with newly diagnosed ovarian cancer, according to disease risk subgroup analyses from the phase 3 ATHENA–MONO study.
Lenvatinib/Pembrolizumab Combo Improves Survival, Responses in Advanced Endometrial Cancer
September 11th 2022, 4:16pm
Lenvatinib plus pembrolizumab maintained clinically meaningful benefits in outcomes vs physician’s choice of therapy for patients with advanced endometrial cancer who received prior platinum-based chemotherapy.
Addition of Enzalutamide to Abiraterone/Prednisolone Deemed Unnecessary in Metastatic HSPC
September 11th 2022, 4:10pm
Although the combination of androgen deprivation therapy, abiraterone acetate, and prednisolone showed a clinically meaningful 7-year improvement in overall survival, AAP plus enzalutamide is not recommended in patients with metastatic hormone-sensitive prostate cancer.
Adjuvant Nivolumab Plus Ipilimumab Fails to Improve DFS in Localized, High-Risk RCC
September 11th 2022, 2:40pm
The combination of adjuvant nivolumab and ipilimumab did not elicit a significant disease-free survival benefit vs placebo in patients with localized, renal cell carcinoma at high risk for relapse after nephrectomy.